BloodStream
Potential Medicaid cuts are looming that could affect our community. Hear how you can take action! We also have exciting news about a clinical trial for von Willebrand’s disease and a special community story from Kayla Klein and her mother, Nancy Rodgers. Plus, Patrick has some fantastic updates from the WFH’s Comprehensive Care Summit in Dubai. Presenting Sponsor: Takeda, visit to learn more. Show Notes: Subscribe: Medicaid Cuts - Take Action Today! Please call or email the offices you visited in March and remind your lawmakers that Medicaid is a...
info_outlineBloodStream
One of our most stacked episodes in a while, featuring a chat and new music with Blood Brother, Trevor Martin. We also have Dr. Richard Lemon on the latest Gene therapy segment discussing the implications of recent hemophilia B gene therapy data. Plus, Allegra Hill and Kimberly Durdin from the only Black-owned birthing center in LA, and the visionary subjects behind our upcoming documentary Deliver Us. AND NYLI’s Shanthi Hegde & Eliza Marie VanZweden! Whew! 😅 Presenting Sponsor: Takeda, visit to learn more. Show Notes: Subscribe: It’s a Whole New World Gene...
info_outlineBloodStream
On April 1st, the Administration announced drastic changes and reductions to the federal health programs, one being the Division of Blood Disorders CDC, greatly affecting the bleeding disorders community. To discuss these concerns, we welcome a familiar face to many of you - Johanna Gray, federal policy advisor to NBDF and all-around wonderful human. Presenting Sponsor: Takeda, visit to learn more. Show Notes: Subscribe: The CDC cuts are of particular concern to our community. The Division of Blood Disorders’ work traces back to the 1980s’ tainted blood crisis,...
info_outlineBloodStream
In this special pop-up episode of the Bloodstream Podcast, host Patrick James Lynch discusses the discontinuation of two Takeda bleeding disorder products with Anthea Cherednichenko, Takeda's VP Franchise Head Hematology and Transplant. Additionally, the 'I'm Fine' segment, sponsored by Sanofi, explores why people cling to the notion of being 'fine' and the importance of embracing vulnerability for true resilience. I’m Fine is presented by @SanofiUS Presenting Sponsor: Takeda, visit to learn more. Show Notes: Subscribe: Connect with BloodStream Media: ...
info_outlineBloodStream
HFA Symposium is this weekend, and we have CEO Dan Kelsey on the podcast to tell us all about it! Plus, a gene therapy segment with the fantastic Brendan Hayes about what she’s hearing in the community about gene therapy for hemophilia B. Presenting Sponsor: Takeda, visit to learn more. Show Notes: Subscribe: It’s a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit or download B SUPPORT wherever you get your apps for more information. Connect with BloodStream Media: ...
info_outlineBloodStream
On this special pop-up episode of the Bloodstream podcast, we’re back with another 'I'm Fine' segment, which delves into the complexities of honesty and mental health. This episode features insights from Gabi Flores on the importance of addressing mental and emotional wellbeing, particularly for those managing chronic conditions. I’m Fine is presented by @SanofiUS Please share this survey with any friends you have with hemophilia A with or without inhibitors, who will help us educate the investment community on the need for new and better therapies. $50...
info_outlineBloodStream
Patrick chats with NBDF CEO, Phil Gattone, after his first Washington Days! Plus, Dr. Nathan Connell gives a terrific ASH Recap full of the latest research and development in bleeding disorders and Amy speaks with co-host, Jessica Richmond about women with bleeding disorders. Presenting Sponsor: Takeda, visit to learn more. Show Notes: Subscribe: It’s a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit or download B SUPPORT wherever you get your apps for more information. ...
info_outlineBloodStream
On this episode we explore the concept of projecting a façade of being 'fine' while struggling internally, especially within the hemophilia community. Featuring insights from Austin Lerner, the episode delves into the importance of expressing vulnerability, embracing un-fine moments, and fostering open communication to truly address one's challenges. I’m Fine is presented by @SanofiUS Presenting Sponsor: Takeda, visit to learn more. Show Notes: Subscribe: Connect with BloodStream Media:
info_outlineBloodStream
We celebrate Rare Disease Day because we love our Rares! Also, folks from WHF join us to share their comprehensive summit and the gene therapy segment is back with a new host and Dr. Mark Kay and genetic counselor, Kaylee Dollerschell. Presenting Sponsor: Takeda, visit to learn more. Show Notes: Subscribe: It’s a Whole New World Gene Therapy Segment brought to you by CSL Behring, which now has a first-of-its-kind hemophilia B treatment. Visit or download B SUPPORT wherever you get your apps for more information. Connect with BloodStream Media:
info_outlineBloodStream
We’ve got distinguished patient advocate Corbin Whittington on the show. Corbin lives with chronic inflammatory demyelinating polyneuropathy (CIDP) and is an executive coach and chair for numerous Boards. He’s an incredible leader in the rare disease community and we’re excited to have him on BloodStream! We’ll also hear from Wes Michael from Rare Patient Voice. Presenting Sponsor: Takeda, visit to learn more. Show Notes: Subscribe: To learn more about our advocacy digital storytelling platform, , head over to Learn more about survey for the bleeding...
info_outlineOn April 1st, the Administration announced drastic changes and reductions to the federal health programs, one being the Division of Blood Disorders CDC, greatly affecting the bleeding disorders community. To discuss these concerns, we welcome a familiar face to many of you - Johanna Gray, federal policy advisor to NBDF and all-around wonderful human.
Presenting Sponsor:
Takeda, visit bleedingdisorders.com to learn more.
Show Notes:
Subscribe:
The CDC cuts are of particular concern to our community. The Division of Blood Disorders’ work traces back to the 1980s’ tainted blood crisis, when CDC investigators were the first to discern and warn of HIV’s transmissibility through blood and blood products. To this day, the Division serves the bleeding disorders community and the nation at large through its public health surveillance activities – including maintaining a laboratory with blood samples dating back to 1996. The Division also funds the collection of key data on bleeding disorders through its “Community Counts” program, and supports educational outreach to increase patient and provider understanding of hemophilia and its complications. Elimination of the Division, its clinical repository, and its institutional knowledge would be a huge loss for the bleeding disorders community.
WHAT CAN YOU DO?
Call the Capitol switchboard: (202) 224-3121
*Anyone can call this number and get connected with their Senators and Representative.
I am calling as a member of the bleeding disorders community and as a constituent to ask that you protect the federal hemophilia programs at the CDC. The recent HHS restructuring eliminated essentially all of the staff at the CDC’s Division of Blood Disorders, where the hemophilia programs are housed. These programs:
-
Help to collect important data on bleeding disorders which in turn helps lead to new and more effective treatments.
-
Provide funding for education and outreach to increase patient and provider understanding of hemophilia.
-
Help to protect the safety of our nation’s blood supply.
I’m very worried about what this means for people with bleeding disorders and our country.
Please work to restore the staffing and activities of the CDC Division of Blood Disorders.
I am relying on you, as my Senator/Representative in Congress, to take action to ensure that the staff for this program are reinstated and to work to protect the funding for this critical program.
**
For years, people with hemophilia A waited for a cure, while inhibitor patients were left behind—but now, after setbacks and failed launches of several gene therapies, investors think patients aren’t interested. By taking this short survey, you can make your voice heard and show investors that our community still wants a durable gene therapy, but this time for both hemophilia A with or without inhibitors. Take the survey here
Connect with BloodStream Media: